• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗新型冠状病毒肺炎的重要药对及其可能机制。

The important herbal pair for the treatment of COVID-19 and its possible mechanisms.

作者信息

Xia Shujie, Zhong Zhangfeng, Gao Bizhen, Vong Chi Teng, Lin Xuejuan, Cai Jin, Gao Hanlu, Chan Ging, Li Candong

机构信息

Research Base of Traditional Chinese Medicine Syndrome, Fujian University of Traditional Chinese Medicine, No.1 Qiuyang Road, Minhou District, 350122, Fuzhou, China.

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, 999078, Macao, China.

出版信息

Chin Med. 2021 Mar 3;16(1):25. doi: 10.1186/s13020-021-00427-0.

DOI:10.1186/s13020-021-00427-0
PMID:33658066
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7927769/
Abstract

BACKGROUND

Coronavirus Disease 2019 (COVID-19) is an unprecedented disaster for people around the world. Many studies have shown that traditional Chinese medicine (TCM) are effective in treating COVID-19. However, it is difficult to find the most effective combination herbal pair among numerous herbs, as well as identifying its potential mechanisms. Herbal pair is the main form of a combination of TCM herbs, which is widely used for the treatment of diseases. It can also help us to better understand the compatibility of TCM prescriptions, thus improving the curative effects. The purpose of this article is to explore the compatibility of TCM prescriptions and identify the most important herbal pair for the treatment of COVID-19, and then analyze the active components and potential mechanisms of this herbal pair.

METHODS

We first systematically sorted the TCM prescriptions recommended by the leading experts for treating COVID-19, and the specific herbs contained in these prescriptions across different stages of the disease. Next, the association rule approach was employed to examine the distribution and compatibility among these TCM prescriptions, and then identify the most important herbal pair. On this basis, we further investigated the active ingredients and potential targets in the selected herbal pair by a network pharmacology approach, and analyzed the potential mechanisms against COVID-19. Finally, the main active compounds in the herbal pair were selected for molecular docking with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) 3CLpro and angiotensin converting enzyme II (ACE2) for further verification.

RESULT

We obtained 32 association rules for the herbal combinations in the selection of TCM treatment for COVID-19. The results showed that the combination of Amygdalus Communis Vas (ACV) and Ephedra sinica Stapf (ESS) had the highest confidence degree and lift value, as well as high support degree, which can be used in almost all the stages of COVID-19, so ACV and ESS (AE) were selected as the most important herbal pair. There were 26 active ingredients and 44 potential targets, which might be related to the herbal pair of AE against COVID-19. The main active ingredients of AE against COVID-19 were quercetin, kaempferol, luteolin, while the potential targets were Interleukin 6 (IL-6), Mitogen-activated Protein Kinase 1 (MAPK)1, MAPK8, Interleukin-1β (IL-1β), and Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) p65 subunit (RELA). The protein-protein interaction (PPI) cluster demonstrated that IL-6 was the seed in the cluster, which plays an important role in connecting other nodes in the PPI network. The potential pathways mainly involved tumor necrosis factor (TNF), Toll-like receptor (TLR), hypoxia-inducible factor-1 (HIF-1), and nucleotide-binding oligomerization domain (NOD)-like receptor (NLRs). The molecular docking results showed that the main active ingredients of AE have good affinity with SARS-COV-2 3CLpro and ACE2, which are consistent with the above analysis.

CONCLUSIONS

There were 32 association rules in the TCM prescriptions recommended by experts for COVID-19. The combination of ACV and EAS was the most important herbal pair for the treatment of COVID-19. AE might have therapeutic effects against COVID-19 by affecting the inflammatory and immune responses, cell apoptosis, hypoxia damage and other pathological processes through multiple components, targets and pathways.

摘要

背景

2019冠状病毒病(COVID-19)对全球人民来说是一场前所未有的灾难。许多研究表明,中药在治疗COVID-19方面有效。然而,在众多草药中难以找到最有效的药对组合,也难以确定其潜在机制。药对是中药配伍的主要形式,广泛应用于疾病治疗。它还能帮助我们更好地理解中药方剂的配伍规律,从而提高疗效。本文旨在探讨中药方剂的配伍规律,确定治疗COVID-19最重要的药对,进而分析该药对的活性成分和潜在机制。

方法

我们首先系统梳理了权威专家推荐的用于治疗COVID-19的中药方剂,以及这些方剂在疾病不同阶段所含的具体草药。接下来,采用关联规则方法研究这些中药方剂之间的分布和配伍情况,进而确定最重要的药对。在此基础上,通过网络药理学方法进一步研究所选药对中的活性成分和潜在靶点,并分析其抗COVID-19的潜在机制。最后,选择药对中的主要活性化合物与严重急性呼吸综合征冠状病毒2(SARS-COV-2)3CL蛋白酶和血管紧张素转换酶II(ACE2)进行分子对接,以进一步验证。

结果

我们获得了32条关于治疗COVID-19的中药方剂中药物组合的关联规则。结果显示,苦杏仁(ACV)与麻黄(ESS)的组合具有最高的置信度和提升值,以及较高的支持度,可用于COVID-19的几乎所有阶段,因此苦杏仁与麻黄(AE)被选为最重要的药对。有26种活性成分和44个潜在靶点,可能与AE药对抗COVID-19有关。AE抗COVID-19的主要活性成分是槲皮素、山奈酚、木犀草素,而潜在靶点是白细胞介素6(IL-6)、丝裂原活化蛋白激酶1(MAPK)1、MAPK8、白细胞介素-1β(IL-1β)和活化B细胞核因子κB(NF-κB)p65亚基(RELA)。蛋白质-蛋白质相互作用(PPI)聚类表明,IL-6是聚类中的种子节点,在连接PPI网络中的其他节点方面发挥重要作用。潜在通路主要涉及肿瘤坏死因子(TNF)、Toll样受体(TLR)、缺氧诱导因子-1(HIF-1)和核苷酸结合寡聚化结构域(NOD)样受体(NLRs)。分子对接结果表明,AE的主要活性成分与SARS-COV-2 3CL蛋白酶和ACE2具有良好的亲和力,与上述分析一致。

结论

专家推荐的治疗COVID-19的中药方剂中有32条关联规则。苦杏仁与麻黄的组合是治疗COVID-19最重要的药对。AE可能通过多种成分、靶点和途径影响炎症和免疫反应、细胞凋亡、缺氧损伤等病理过程,从而对COVID-19产生治疗作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/bc1734113bbf/13020_2021_427_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/92035b787e58/13020_2021_427_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/10ea3b48233e/13020_2021_427_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/6c8c18de1d93/13020_2021_427_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/0910050d930a/13020_2021_427_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/652af8ba6ef4/13020_2021_427_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/83e2034f1705/13020_2021_427_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/bc1734113bbf/13020_2021_427_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/92035b787e58/13020_2021_427_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/10ea3b48233e/13020_2021_427_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/6c8c18de1d93/13020_2021_427_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/0910050d930a/13020_2021_427_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/652af8ba6ef4/13020_2021_427_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/83e2034f1705/13020_2021_427_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/acf7/7931337/bc1734113bbf/13020_2021_427_Fig7_HTML.jpg

相似文献

1
The important herbal pair for the treatment of COVID-19 and its possible mechanisms.用于治疗新型冠状病毒肺炎的重要药对及其可能机制。
Chin Med. 2021 Mar 3;16(1):25. doi: 10.1186/s13020-021-00427-0.
2
Herbal combinations against COVID-19: A network pharmacology, molecular docking and dynamics study.对抗新型冠状病毒肺炎的草药组合:一项网络药理学、分子对接及动力学研究
J Integr Med. 2023 Nov;21(6):593-604. doi: 10.1016/j.joim.2023.09.001. Epub 2023 Sep 26.
3
Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.网络药理学与实验验证揭示麻杏石甘汤防治 2019 年冠状病毒病(COVID-19)的潜在作用。
J Ethnopharmacol. 2021 May 10;271:113854. doi: 10.1016/j.jep.2021.113854. Epub 2021 Jan 26.
4
Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.麻黄中的活性成分破坏 ACE2 与 SARS-CoV-2 RBD 的相互作用:有效的 COVID-19 治疗药物。
J Ethnopharmacol. 2021 Oct 5;278:114303. doi: 10.1016/j.jep.2021.114303. Epub 2021 Jun 5.
5
Insights into forsythia honeysuckle (Lianhuaqingwen) capsules: A Chinese herbal medicine repurposed for COVID-19 pandemic.连花清瘟胶囊的见解:一种被重新用于应对新冠疫情的中药。
Phytomed Plus. 2021 May;1(2):100027. doi: 10.1016/j.phyplu.2021.100027. Epub 2021 Jan 16.
6
In Silico Screening of Potential Chinese Herbal Medicine Against COVID-19 by Targeting SARS-CoV-2 3CLpro and Angiotensin Converting Enzyme II Using Molecular Docking.基于分子对接的针对 SARS-CoV-2 3CLpro 和血管紧张素转化酶 II 的新冠病毒潜在中草药的计算机筛选
Chin J Integr Med. 2020 Jul;26(7):527-532. doi: 10.1007/s11655-020-3476-x. Epub 2020 Jul 6.
7
Network Pharmacology Analysis of Traditional Chinese Medicine for Treating Psoriasis: Identifying Core Components, Mechanisms, and Dosing Patterns.治疗银屑病的中药网络药理学分析:确定核心成分、作用机制和给药模式
Altern Ther Health Med. 2024 Jul 19.
8
Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.基于网络药理学和分子对接的方法研究化湿败毒方治疗 COVID-19 的分子作用靶点及机制。
Drug Dev Ind Pharm. 2020 Aug;46(8):1345-1353. doi: 10.1080/03639045.2020.1788070. Epub 2020 Jul 8.
9
Identifying potential treatments of COVID-19 from Traditional Chinese Medicine (TCM) by using a data-driven approach.利用数据驱动的方法从中医药中寻找 COVID-19 的潜在治疗方法。
J Ethnopharmacol. 2020 Aug 10;258:112932. doi: 10.1016/j.jep.2020.112932. Epub 2020 May 4.
10
Examining the effector mechanisms of Xuebijing injection on COVID-19 based on network pharmacology.基于网络药理学探讨血必净注射液对新型冠状病毒肺炎的效应机制
BioData Min. 2020 Oct 16;13:17. doi: 10.1186/s13040-020-00227-6. eCollection 2020.

引用本文的文献

1
AI-assisted literature exploration of innovative Chinese medicine formulas.人工智能辅助探索创新中药方剂的文献研究
Front Pharmacol. 2024 Mar 22;15:1347882. doi: 10.3389/fphar.2024.1347882. eCollection 2024.
2
Integration of Omics Data and Network Models to Unveil Negative Aspects of SARS-CoV-2, from Pathogenic Mechanisms to Drug Repurposing.整合组学数据与网络模型以揭示新冠病毒的负面因素,从致病机制到药物再利用
Biology (Basel). 2023 Aug 31;12(9):1196. doi: 10.3390/biology12091196.
3
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products.

本文引用的文献

1
Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients.致病性T细胞和炎性单核细胞在重症COVID-19患者中引发炎症风暴。
Natl Sci Rev. 2020 Jun;7(6):998-1002. doi: 10.1093/nsr/nwaa041. Epub 2020 Mar 13.
2
Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming.清肺排毒汤通过抗病毒、抗炎活性和代谢编程来预防 COVID-19 损伤。
Biomed Pharmacother. 2020 Sep;129:110281. doi: 10.1016/j.biopha.2020.110281. Epub 2020 May 25.
3
COVID-19: asymptomatic carrier transmission is an underestimated problem.
MYC 癌基因:天然产物治疗癌症的可用药靶。
Aging Dis. 2024 Apr 1;15(2):640-697. doi: 10.14336/AD.2023.0520.
4
Therapeutic drug combinations against COVID-19 obtained by employing a collaborative filtering method.通过采用协同过滤方法获得的抗新型冠状病毒肺炎治疗药物组合。
Heliyon. 2023 Mar;9(3):e14023. doi: 10.1016/j.heliyon.2023.e14023. Epub 2023 Feb 25.
5
Renoprotective Effects of Luteolin: Therapeutic Potential for COVID-19-Associated Acute Kidney Injuries.木犀草素的肾保护作用:COVID-19 相关急性肾损伤的治疗潜力。
Biomolecules. 2022 Oct 23;12(11):1544. doi: 10.3390/biom12111544.
6
Efficacy and safety of a Chinese herbal formula Maxing Ganshi Decoction in children with community-acquired pneumonia: A randomized, double-blind, placebo-controlled, multicenter trial.中药方剂麻杏甘石汤治疗儿童社区获得性肺炎的疗效与安全性:一项随机、双盲、安慰剂对照、多中心试验
Front Pharmacol. 2022 Sep 2;13:948831. doi: 10.3389/fphar.2022.948831. eCollection 2022.
7
A Computational Approach to Elucidate the Interactions of Chemicals From Targeted Toward SARS-CoV-2 Main Protease Inhibition for COVID-19 Treatment.一种用于阐明针对新冠病毒主要蛋白酶抑制作用的化学物质相互作用的计算方法,以用于新冠治疗。
Front Med (Lausanne). 2022 Jun 15;9:907583. doi: 10.3389/fmed.2022.907583. eCollection 2022.
8
A Network Pharmacology Approach for Uncovering the Antitumor Effects and Potential Mechanisms of the Sijunzi Decoction for the Treatment of Gastric Cancer.基于网络药理学方法揭示四君子汤治疗胃癌的抗肿瘤作用及潜在机制
Evid Based Complement Alternat Med. 2022 Apr 12;2022:9364313. doi: 10.1155/2022/9364313. eCollection 2022.
9
Clinical data mining reveals Gancao-Banxia as a potential herbal pair against moderate COVID-19 by dual binding to IL-6/STAT3.临床数据挖掘揭示甘草-半夏可能通过双重结合 IL-6/STAT3 成为治疗中度 COVID-19 的一对草药。
Comput Biol Med. 2022 Jun;145:105457. doi: 10.1016/j.compbiomed.2022.105457. Epub 2022 Mar 26.
10
Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review.草药防治冠状病毒及其潜在机制的研究进展。
Bioengineered. 2022 Mar;13(3):5480-5508. doi: 10.1080/21655979.2022.2036521.
新型冠状病毒肺炎:无症状携带者传播是一个被低估的问题。
Epidemiol Infect. 2020 Jun 11;148:e116. doi: 10.1017/S0950268820001235.
4
Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).中药治疗 2019 年冠状病毒病(COVID-19)的潜在作用机制研究进展。
Pharmacol Res. 2020 Aug;158:104939. doi: 10.1016/j.phrs.2020.104939. Epub 2020 May 21.
5
Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis.中西医结合治疗 2019 年冠状病毒病(COVID-19)的疗效和安全性:系统评价和荟萃分析。
Pharmacol Res. 2020 Aug;158:104896. doi: 10.1016/j.phrs.2020.104896. Epub 2020 May 11.
6
Treatment efficacy analysis of traditional Chinese medicine for novel coronavirus pneumonia (COVID-19): an empirical study from Wuhan, Hubei Province, China.中药治疗新型冠状病毒肺炎(COVID-19)的疗效分析:来自中国湖北省武汉市的实证研究
Chin Med. 2020 Apr 15;15:34. doi: 10.1186/s13020-020-00317-x. eCollection 2020.
7
Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2).连花清瘟对新型冠状病毒(SARS-CoV-2)具有抗病毒和抗炎作用。
Pharmacol Res. 2020 Jun;156:104761. doi: 10.1016/j.phrs.2020.104761. Epub 2020 Mar 20.
8
Health security capacities in the context of COVID-19 outbreak: an analysis of International Health Regulations annual report data from 182 countries.新冠疫情背景下的卫生安全能力:对 182 个国家《国际卫生条例》年度报告数据的分析。
Lancet. 2020 Mar 28;395(10229):1047-1053. doi: 10.1016/S0140-6736(20)30553-5. Epub 2020 Mar 18.
9
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.血管紧张素转换酶2(ACE2)作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的受体:分子机制与潜在治疗靶点
Intensive Care Med. 2020 Apr;46(4):586-590. doi: 10.1007/s00134-020-05985-9. Epub 2020 Mar 3.
10
Clinical Characteristics of Coronavirus Disease 2019 in China.《中国 2019 年冠状病毒病临床特征》
N Engl J Med. 2020 Apr 30;382(18):1708-1720. doi: 10.1056/NEJMoa2002032. Epub 2020 Feb 28.